loading
Salarius Pharmaceuticals Inc stock is traded at $0.70, with a volume of 24,667. It is down -1.44% in the last 24 hours and down -33.33% over the past month. Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$0.7102
Open:
$0.6814
24h Volume:
24,667
Relative Volume:
0.02
Market Cap:
$1.49M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
-0.109
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
+11.09%
1M Performance:
-33.33%
6M Performance:
-74.36%
1Y Performance:
-73.18%
1-Day Range:
Value
$0.6812
$0.7001
1-Week Range:
Value
$0.598
$0.75
52-Week Range:
Value
$0.4519
$7.20

Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile

Name
Name
Salarius Pharmaceuticals Inc
Name
Phone
346-772-0346
Name
Address
2450 HOLCOMBE BLVD, HOUSTON
Name
Employee
2
Name
Twitter
@SalariusPharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
SLRX's Discussions on Twitter

Compare SLRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SLRX
Salarius Pharmaceuticals Inc
0.70 1.51M 4.70M -4.99M -5.29M -6.42
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-27-20 Initiated Ladenburg Thalmann Buy

Salarius Pharmaceuticals Inc Stock (SLRX) Latest News

pulisher
Jul 23, 2025

Is Salarius Pharmaceuticals Inc. a good long term investmentFree Stock Chart Pattern Guide - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Salarius Pharmaceuticals Inc. stockHigh-yield investments - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Salarius Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange - Investing.com

Jul 21, 2025
pulisher
Jul 20, 2025

Salarius Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough stock performance - printweek.in

Jul 20, 2025
pulisher
Jul 16, 2025

Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% – What’s Next? - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

How Salarius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Return Analysis - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Salarius Pharmaceuticals Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Salarius Pharmaceuticals Inc. stock price move sharplyShort Squeeze Radar - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance - MSN

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals Granted Extension to Regain Compliance With Nasdaq's Stockholders' Equity Requirement - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy Therapeutics - Quiver Quantitative

Jul 14, 2025
pulisher
Jul 14, 2025

SLRX gets Nasdaq extension; equity deadline moves to late-July 2025 | NDSN SEC FilingForm 8-K - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Pharmaceuticals Granted Additional Extension to - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

Salarius Secures Critical Nasdaq Extension Amid $2.5M Equity Requirement Challenge - Stock Titan

Jul 14, 2025
pulisher
Jul 10, 2025

Salarius Pharmaceuticals’ Seclidemstat Demonstrates - GlobeNewswire

Jul 10, 2025
pulisher
Jul 09, 2025

Salarius Pharmaceuticals, Inc. Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewswire

Jul 09, 2025
pulisher
Jul 09, 2025

Breakthrough Studies Support Salarius Cancer Drug Effectiveness While Clinical Trials Show Promise - Stock Titan

Jul 09, 2025
pulisher
Jul 09, 2025

Salarius Pharmaceuticals reports progress in LSD1 inhibitor study, merger with Decoy Therapeutics. - AInvest

Jul 09, 2025
pulisher
Jul 08, 2025

Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance - Investing.com Nigeria

Jul 08, 2025
pulisher
Jul 08, 2025

Salarius Pharmaceuticals Approves Reverse Stock Split - TipRanks

Jul 08, 2025
pulisher
Jun 18, 2025

Why Is Salarius Pharmaceuticals Stock (SLRX) Up 110% Today? - The Globe and Mail

Jun 18, 2025
pulisher
Jun 18, 2025

Salarius Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SLRX - Benzinga

Jun 18, 2025
pulisher
Jun 17, 2025

What's Going On With Salarius Pharmaceuticals Shares Today? - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Why Lennar Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

Jun 17, 2025
pulisher
Jun 16, 2025

Salarius Pharmaceuticals Granted Nasdaq Compliance Extension - TipRanks

Jun 16, 2025
pulisher
Jun 11, 2025

Salarius Pharmaceuticals adjusts merger terms amid market shifts By Investing.com - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

Salarius Pharmaceuticals adjusts merger terms amid market shifts - Investing.com Australia

Jun 11, 2025
pulisher
Jun 11, 2025

Salarius Pharmaceuticals Enters Second Amendment To Merger Agreement With DecoySEC Filing - MarketScreener

Jun 11, 2025

Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Cap:     |  Volume (24h):